Drug Trial Radar · NCT07768111
Clinical Study on Drug Interactions of Flonoltinib Maleate Tablets
Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Oct 30, 2026
Primary completion
Dec 30, 2026
Study completion Jan 31, 2027
Sponsor
- Lead sponsor
- Chengdu Zenitar Biomedical Technology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Aug 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a single center, open label, fixed sequence drug interaction study to evaluate the effects of CYP3A4 inhibitor itraconazole and CYP3A4 inducer rifampicin on the pharmacokinetic characteristics of a single oral dose of flonotinib maleate tablets. This trial includes screening period, baseline period, medication observation period, and follow-up period, totaling approximately 3 months.
Conditions
- Drug Interaction Research
Interventions
75mg FlonoltinibDrug
Day 1 and Day 12 : 75mg Flonoltinib on an empty stomach in the morning
100mg FlonoltinibDrug
Day 1 and Day 19 : 100mg Flonoltinib on an empty stomach in the morning
Primary outcomes
What the sponsor says the trial is designed to measure.
- CmaxTime frame: Until 144hours
- TmaxTime frame: Until 144hours
- AUC0-tTime frame: Until 144hours
- t1/2Time frame: Until 144hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Second Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.